Alnylam Pharmaceuticals
ALNY
#571
Rank
NZ$70.26 B
Marketcap
NZ$529.77
Share price
-1.18%
Change (1 day)
21.69%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -NZ$0.41 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$3.21 Billion. In 2024 the company made an earning of -NZ$0.41 Billion, an increase over its 2023 earnings that were of -NZ$0.54 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-NZ$0.41 Billion-24.59%
2023-NZ$0.54 Billion-67.84%
2022-NZ$1.66 Billion36.93%
2021-NZ$1.21 Billion-8.04%
2020-NZ$1.32 Billion-15.66%
2019-NZ$1.56 Billion12.23%
2018-NZ$1.39 Billion62.91%
2017-NZ$0.86 Billion17.78%
2016-NZ$0.73 Billion43.44%
2015-NZ$0.51 Billion60.69%
2014-NZ$0.32 Billion98.2%
2013-NZ$0.16 Billion
2011-NZ$93.35 Million27.48%
2010-NZ$73.23 Million-10.92%
2009-NZ$82.21 Million95.77%
2008-NZ$42 Million
2006-NZ$67.27 Million-9.13%
2005-NZ$74.03 Million34.74%
2004-NZ$54.95 Million36.79%
2003-NZ$40.17 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
NZ$27.84 B 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$15.49 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$8.90 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-NZ$0.43 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-NZ$80.77 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-NZ$0.28 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$3.66 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.23 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA